Dr. William C. Biggs, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
9092 Westgate Pkwy W
Amarillo, TX 79124
Who else practices at this address →
Potter County includes primary care (100% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 825
Licensed in Texas since 1983, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1982Medical school: University of Texas Southwestern Medical School at Dallas
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
TX license G3157 (first issued 1983; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bsa Hospital Amarillo, TX
- Northwest Texas Hospital Amarillo, TX
Medical groups
- Amarillo Medical Specialists,llp (42 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 825
- Services billed
- 22,206
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 2,214 | 811 |
| Established patient office or other outpatient visit, 30-39 minutes | 2,213 | 808 |
| Bilirubin level, direct | 2,092 | 779 |
| Blood test, comprehensive group of blood chemicals | 2,086 | 779 |
| Injection, denosumab, 1 mg | 2,040 | 20 |
| Hemoglobin a1c level | 1,628 | 506 |
| Blood test, lipids (cholesterol and triglycerides) | 1,626 | 526 |
| Ldl cholesterol level | 1,592 | 514 |
| Thyroxine (thyroid chemical), free | 1,124 | 727 |
| Blood test, thyroid stimulating hormone (tsh) | 1,115 | 723 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levothyroxine Sodium Other prescribers in Amarillo, TX | 543 |
| Ozempic (semaglutide) Other prescribers in Amarillo, TX | 272 |
| Metformin Hcl Other prescribers in Amarillo, TX | 268 |
| Tresiba Flextouch U-100 (insulin degludec) Other prescribers in Amarillo, TX | 164 |
| Atorvastatin Calcium Other prescribers in Amarillo, TX | 162 |
| Lisinopril Other prescribers in Amarillo, TX | 149 |
| Lantus Solostar (insulin glargine,hum.rec.anlog) Other prescribers in Amarillo, TX | 141 |
| Tresiba Flextouch U-200 (insulin degludec) Other prescribers in Amarillo, TX | 129 |
| Jardiance (empagliflozin) Other prescribers in Amarillo, TX | 110 |
| Gabapentin Other prescribers in Amarillo, TX | 100 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 68 payments worth $3,560 in total to this clinician.
| Insulet Corporation | $1,923 |
|---|---|
| Amgen Inc. | $334 |
| Novo Nordisk Inc | $314 |
| Sanofi-aventis U.S. LLC | $246 |
| Alexion Pharmaceuticals, Inc. | $84.22 |
| Sequel Med Tech, LLC | $68.55 |
| AbbVie Inc. | $59.59 |
| Abbott Laboratories | $56.92 |
| Food and Beverage | $1,931 |
|---|---|
| Travel and Lodging | $1,628 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Insulet Corporation Oct 3, 2025 | Travel and Lodging OMNIPOD · Insulin Pump · travel to Burlington, MA | $641 |
| Insulet Corporation Oct 3, 2025 | Travel and Lodging OMNIPOD · Insulin Pump · travel to Burlington, MA | $375 |
| Insulet Corporation Oct 3, 2025 | Travel and Lodging OMNIPOD · Insulin Pump · travel to Burlington, MA | $323 |
| Insulet Corporation Oct 4, 2025 | Travel and Lodging OMNIPOD · Insulin Pump · travel to Burlington, MA | $132 |
| Insulet Corporation Oct 4, 2025 | Travel and Lodging OMNIPOD · Insulin Pump · travel to Burlington, MA | $97.12 |
| Insulet Corporation Aug 17, 2025 | Travel and Lodging OMNIPOD · Insulin Pump · travel to Burlington, MA | $60.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $260,849 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - Study name not reported
Novo Nordisk As - Study name not reported
Novo Nordisk As - Study name not reported
Novo Nordisk As - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.